News & Press

August 27, 2008—It has been one year since Bob Coughlin took the reins at MBC. In this letter, he shares information on what the council has been doing for members this past year—and where the organization is going next.

Read more

Join us for a day of golf - and support our efforts to educate the next generation!

On Friday, Sept. 5, the MBC will hold its 14th Annual Golf Classic Fundraiser, Tee Off for Biotechnology Education, to benefit the Massachusetts Biotechnology Education Foundation.

MBC member companies can participate in a number of ways. You are invited to compete in the tournament in teams of four, sponsor the event, or make a donation to attend the reception following the tournament. With 350 athletes/biotech industry leaders in attendance, networking opportunities during and after the tournament abound.
Register Today

President Bush has signed multi-billion dollar legislation addressing the nation's mortgage and housing crises that also contains an economic stimulus jolt for the biotechnology industry.

After five years of frustration in Congress, biotechnology companies with significant venture capital backing are on the verge of once again qualifying for SBIR (Small Business Innovation Research) grants, thanks in large measure to the persistent advocacy of MBC and its members.

On June 16, at Boston's Joslin Diabetes Center, Massachusetts Governor Deval Patrick signed into law the state's landmark Life Sciences Initiative (LSI), then immediately flew to San Diego with legislative leadership to tout the plan in front of the world's biotechnology industry at the BIO 2008 International Convention.

In the Message of Hope radio series, you hear real stories of three Massachusetts researchers and a clinical trials manager who work each day to produce cures for unmet medial needs. These talented individuals come from a cross-section of the Massachusetts Biotechnology Council Membership (MBC): an academic research institution, a small biotechnology company with 15 employees, a medium sized, public biotechnology company pushing for their first product, and a large biopharmaceutical company working on its next promising therapy.